ArticleMedical hypotheses2021
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
Article in Medical hypotheses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Review
- Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- The direct correlation between microbiota and SARS-CoV-2 infectious disease.Inflammopharmacology · 2023Review
- Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.Inflammopharmacology · 2022Article
- Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.International journal of molecular sciences · 2022Article
- Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.Journal of reproductive immunology · 2022Review
- A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?Immunologic research · 2022Review
- COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.Irish journal of medical science · 2022Article
- Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.Molecular biology reports · 2022Article
- Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Review
- Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.Archives of medical research · 2021Review
- Plausible Positive Effects of Statins in COVID-19 Patient.Cardiovascular toxicology · 2021Review
- Logistics management provides greater efficiency, governance and compliance.International journal of clinical pharmacy · 2021Article
- Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.Wiener klinische Wochenschrift · 2021Article
- The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.Wiener klinische Wochenschrift · 2021Review
- The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Brief review of the mRNA vaccines COVID-19.Inflammopharmacology · 2021Review
- Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.Cardiovascular toxicology · 2021Article
- Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.Respiratory medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On March 11, 2020 the World Health Organization (WHO) declared the state of global pandemic caused by the new SARS-CoV-2 (COVID-19). To date, no antivirals directed against SARS-CoV-2 or effective vaccines to combat the viral infection are available. Severe acute respiratory syndrome caused by SARS-CoV-2 is treated empirically with antivirals, anti-inflammatory, anticoagulants. The approval of an effective vaccine still takes time. In this state, it may be useful to find new therapeutic solutions from drugs already on the market. Recent hypotheses suggest that the use of AT-1 receptor antagonists (ARB) in combination with neprilisin inhibitors (NEPi) could indirectly provide clinical benefits to patients with SARS-CoV-2 and cardiac involvement. In this article we investigate and describe a possible innovative pharmacological approach for the treatment of the most severe stages of COVID-19 infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.